Latest Regulatory Engagement News

Telix Pharmaceuticals has announced that Part 1 of its ProstACT Phase 3 trial for TLX591-Tx met its primary safety and dosimetry objectives, with no new safety concerns. The study’s success supports ongoing global enrolment in Part 2 and regulatory engagement in the US.

Native Mineral Resources has reported impressive shallow high-grade gold intercepts at its Podosky deposit, reinforcing plans to commence mining by April 2026. The results bolster confidence in the deposit’s open-pit potential and support ongoing development at the Ravenswood Gold Project.

LTR Pharma has finalised recruitment for its Phase II clinical trial of SPONTAN, a rapid-acting intranasal spray for erectile dysfunction, with initial results expected in the second quarter of 2026.

Environmental Clean Technologies Limited reported a $2.58 million loss for the half-year ended December 2025, marking a strategic pivot with the acquisition of Terrajoule Pty Ltd and exclusive rights to innovative remediation technology.

Paradigm Biopharmaceuticals reports a sharp rise in half-year losses as it intensifies investment in its pivotal Phase 3 trial for knee osteoarthritis, setting sights on a critical interim analysis in mid-2026. The company also expands its osteoarthritis pipeline and maintains strong funding amid a strengthening biotech sector.

Patrys Limited reported a near doubling of its half-year loss to $3.02 million, driven by restructuring and a strategic pivot including the acquisition of Reliis Pty Ltd. The company is advancing a dual-platform biotech strategy combining a clinical-stage CNS asset with its proprietary antibody platform.

Neurizon Therapeutics has commenced dosing in a major Phase 2/3 trial of its lead drug NUZ-001 for ALS, marking a critical step in advancing treatment options for this devastating disease.

Critical Resources Limited highlights significant progress in its lithium and gold projects across Canada and New Zealand, alongside pioneering work in next-generation solid-state lithium-ion batteries.

NeuroScientific Biopharmaceuticals reported a $1.7 million loss for the half-year ending December 2025, driven by ongoing R&D investments. The company progressed clinical treatments for Crohn’s disease and glaucoma, alongside key leadership appointments and strategic partnerships.

Island Pharmaceuticals reports a 213.8% increase in half-year loss to $4.81 million, driven by strategic acquisition and clinical development investments. The company advances its antiviral portfolio with Galidesivir and ISLA-101, supported by strong US regulatory engagement and a $9 million capital raise.

RocketDNA Ltd reported a 6% increase in revenue to AUD 76.83 million for the year ended 31 December 2025, expanding its autonomous drone footprint across Australia and Africa while securing major mining contracts.

Greenwing Resources has significantly enhanced the economics of its Que River Project following a sharp rise in key metal prices, nearly doubling projected cash flows and advancing a two-stage development plan.